HONG
KONG - Scientists say they have
extracted a powerful antibody from a recovered dengue patient in Singapore that
can smother and choke the virus to death, a discovery that they hope may offer
a new weapon to control the deadly disease.
There
is currently no cure for dengue which kills 20,000 people a year, many of them
children. Physicians can only manage the symptoms.
The
antibody recovered from Singapore was among 200,000 taken from 100 recovered
patients and appeared capable of killing all known strains of the subtype 1
dengue virus, said a paper published on Thursday in the journal Science
Translational Medicine.
There
are four disparate subtypes of the dengue virus, which causes an intensely
painful fever.
"It
kills the dengue virus even before it can get a chance to infect any
cell," said Lok Shee-Mei of the Duke-NUS Graduate Medical School and a
member of the research team.
In
mice experiments, the researchers saw how the antibody stretched itself across
the surface proteins of the virus, smothering it and locking it down.
"When
the virus wants to infect cells, it needs to breathe and expand, so its surface
proteins undergo slight changes ... but this antibody binds across the surface
proteins, so the proteins cannot change in any sense. The virus is unable to
infect," Lok said by telephone from Singapore.
Compared
to some other anti-dengue chemical compounds in development, the antibody
killed more viruses and acted quicker, said lead author Paul MacAry,
microbiology associate professor at the National University of Singapore's
faculty of medicine.
The
researchers plan to test the antibody soon in people infected with dengue
subtype 1 in clinical trials in Singapore.
Meanwhile,
the team is combing its library and hopes to find similarly powerful antibodies
that specifically target dengue subtypes 2, 3 and 4.
MacAry
said his team have discovered an antibody that targets subtype 2, but it was
still in the early phase of testing.
"Ninety
per cent of all dengue in Singapore is either type 1 or 2. This means that
within the next 6 months to a year, we are going to have two antibodies that
will allow us to treat most patients in Singapore," he said.
Reuters
No comments:
Post a Comment